Role of MabCampath in allogeneic transplantation.
Alemtuzumab reduces the incidence of acute and chronic GvHD following stem cell transplantation and reduces GvHD-related mortality. There is a delay in immune reconstitution and an increased incidence of viral infections with the use of alemtuzumab, however many of these infections are asymptomatic, and at least in the case of CMV in the sibling setting, do not adversely effect transplant-related mortality. Disease relapse appears more common but approaches incorporating DLI may offset this tendency in immune responsive malignancies. Delivery of these therapies in a less toxic manner remains a priority for future research.
Peggs
K S
KS
Royal Free and University College London Medical School, London, UK.
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D017710:Lymphocyte Transfusion; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab